As ZEB2 immunopositivity correlated with decreased OS and DFS observed in patients receiving FOLFOX (Fig. 1), we hypothesised that ZEB2 may be responsible for resistance of CRC cells to components of this regimen. Here, ZEB2 is linked to colorectal carcinoma.